Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Progesterone‑11‑alpha‑ol‑hemisuccinate is a synthetic steroid ester, specifically the O-succinoyl derivative of 11α-hydroxyprogesterone. It is classified as a small molecule and functions as a progestogen analog. The compound is structurally related to both succinic acid and the endogenous hormone progesterone via its modification at the C‑11 position with a hemisuccinic acid moiety. This modification may alter its solubility or pharmacokinetic properties compared to native progesterone, but there are no approved therapeutic indications or clinical uses reported for this compound. Its mechanism of action would be expected to involve agonism at the progesterone receptor, similar to other progestins[2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on progesterone-11-alpha-ol-hemisuccinate.